Search the Newsreel

Legend Biotech stock downgraded at Oppenheimer (LEGN:NASDAQ)

Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform following the resignation of its CEO, competitive pressures, and reduced M&A prospects. The analyst cited these factors as reasons for the downgrade. Legend Biotech's shares saw a decline on Wednesday after the announcement.

Oppenheimer downgrades Legend Biotech stock rating on M&A concerns

Oppenheimer downgraded Legend Biotech (NASDAQ:LEGN) to Perform from Outperform, lowering its price target to $40 due to diminished M&A prospects, particularly after Johnson & Johnson was removed as a potential buyer. The firm also cited concerns over the CEO's departure, financing issues, and weak …

RBC Adjusts Price Target on Legend Biotech to $58 From $59, Maintains Outperform Rating

RBC Capital Markets has adjusted its price target for Legend Biotech (LEGN) to $58, down from $59, while reiterating an Outperform rating on the stock. This revision comes amidst recent news for Legend Biotech, including a downgrade from Oppenheimer and the company reporting its …

Legend Biotech Releases Q2 2026 Financial Results

Legend Biotech (LEGN) reported strong Q2 2026 financial results, with adjusted earnings of $0.16 per share, surpassing estimates. The company generated $387.5 million in revenue, largely driven by its CARVYKTI collaboration, indicating significant growth and market penetration for its cell therapy platform. Wall Street …

Legend Turns Profitable In Q2 As CARVYKTI Sales Jump By 50%

(RTTNews) - Legend Biotech Corporation (LEGN) released financial results for the second quarter ended June 30, 2026. The commercial-stage company turned profitable in the second quarter, compared with a loss in the prior-year quarter, driven by higher collaboration revenue and improved operating income. For …

Legend Biotech (LEGN) Stock Rebounds As Profit Arrives But Carvykti Risk Persists

Legend Biotech (LEGN) Returned To Profit, Is The Stock Still Cheap?

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Interim Chief Executive Officer - Alan BashChief Financial Officer - Carlos SantosInterim Head of R&D - Yuhong QiuDirector of Investor Relations - Caroline LeCates Paul TAKEAWAYS Worldwide Net …

Legend Biotech Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LEGN) 2026-08-11

This article first appeared on GuruFocus. Total Revenue: Increased 52% year over year, driven by continued CARVYKTI demand and commercial expansion. CARVYKTI Net Trade Sales: Approximately $657 million worldwide, representing 50% year-over-year growth and 10% sequential growth. U.S. CARVYKTI Sales: Increased 32% year over …

Legend Biotech Corp (LEGN) (Q2 2026) Earnings Call Highlights: First Profitable Quarter Driven ...

This article first appeared on GuruFocus. Total Revenue: Increased 52% year over year, driven by continued CARVYKTI demand and commercial expansion. CARVYKTI Net Trade Sales: Approximately $657 million worldwide, representing 50% year-over-year growth and 10% sequential growth. U.S. CARVYKTI Sales: Increased 32% year over …

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Legend Biotech (NASDAQ:LEGN) surged 6% after reporting its first-ever profitable quarter in Q2 2026, with revenue of $387.5 million beating estimates and adjusted EPS of $0.16 doubling consensus. The strong performance was driven by CARVYKTI net sales reaching $657 million, up 50% year-over-year, and …

Earnings Flash (LEGN) Legend Biotech Corporation Reports Q2 Revenue $387.5M, Vs. FactSet Est of $356.0M

Legend Biotech Corporation (LEGN) reported strong financial results for Q2, with revenues reaching $387.5 million, significantly surpassing the FactSet estimate of $356.0 million. This earnings flash highlights the company's robust revenue performance for the quarter.

Legend Biotech (NASDAQ:LEGN) Shares Gap Up After Strong Earnings

Legend Biotech Q2 Earnings Call Highlights

Key Points Interested in Legend Biotech Corporation Sponsored ADR? Here are five stocks we like better. CARVYKTI sales rose sharply: Worldwide net trade sales increased 50% year over year to approximately $657 million, driven by earlier-line treatment adoption in the U.S. and international expansion …

Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5%

Legend Biotech reported stronger-than-expected Q2 2026 results, achieving its first quarter of company-wide profitability with adjusted earnings of $0.16 per share and revenue of $387.5 million, significantly beating analyst estimates. The company's lead CAR-T therapy, CARVYKTI, saw worldwide net trade sales increase 50% year-over-year, …

Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The CEO who helped guide development of the top-selling cell therapy for multiple myeloma will take the reins of a young startup …

Legend Biotech stock rises 5% on earnings and revenue beat

Pipette dropping liquid into a test tube ©Adobe Stock Images Legend Biotech Corporation (NASDAQ:LEGN) shares gained 5.5% in pre-market trading on Tuesday after the pharmaceutical company delivered better-than-expected second-quarter earnings and revenue, supported by continued growth in CARVYKTI sales. Adjusted earnings came in at …

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

Legend Biotech USA Inc. CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million Expanded CARVYKTI® availability to 348 global sites and 19 global markets with the launch of Ireland Achieved first clinical proof-of-concept for LB2501, …

Earnings Flash (LEGN) Legend Biotech Corporation Posts Q2 Adjusted Net Income $0.16 per Share

Legend Biotech Corporation reported an adjusted net income of $0.16 per share for the second quarter of 2026. This financial announcement was made on August 11, 2026, and also included a reported Q2 revenue of $387.5 million, surpassing FactSet's estimate of $356.0 million. The …

Legend Biotech in spotlight: Earnings test Carvykti momentum

Legend Biotech is set to report its second-quarter earnings, with investors focused on the sustained growth of its CAR-T therapy, Carvykti, amidst increasing competition and a recent CEO departure. Analysts anticipate improved earnings and revenue for the quarter, but concerns linger regarding competitive threats …

Legend Biotech (LEGN) CEO Shift: Will CARVYKTI Leadership Rebalance Risk Between Pipeline and Commercial Focus?

Legend Biotech recently announced a leadership change, with CEO Ying Huang stepping down and Alan Bash, President of the CARVYKTI Business Unit, appointed as Interim CEO. This shift places an executive closely associated with the flagship CARVYKTI franchise at the helm, potentially rebalancing the …

1,915,056 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. has acquired 1,915,056 shares of Legend Biotech Corporation (NASDAQ:LEGN) worth approximately $55.3 million, giving it a 1.03% stake. Institutional investors now own 70.89% of the company, and analysts generally have a "Moderate Buy" rating with an average price target of …

Legend Biotech Details Compensation Package for Interim CEO Alan Bash

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts

Legend Biotech Corporation (NASDAQ:LEGN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $55.29. While the company reported a 56.5% year-over-year revenue increase to $305.1 million, it missed EPS estimates with an adjusted loss of $0.03 per …

Legend Biotech (LEGN) Expected to Announce Earnings on Tuesday

Legend Biotech Number of Employees 2026 | Employee Count & Headcount Data

Legend Biotech Corp. (NASDAQ: LEGN) has approximately 6,378 employees worldwide as of March 2026, representing a 91.4% growth since 2023. The company is actively hiring, though job postings have declined, and employee sentiment is negative. Its workforce is concentrated in Western Europe and North …

RBC cuts Legend Biotech stock price target to $59 on model updates

RBC Capital has lowered its price target for Legend Biotech Corp. (NASDAQ:LEGN) to $59 from $63, while maintaining an Outperform rating, citing model updates. Despite the reduction, the firm believes Legend Biotech's in vivo CAR-T technology could unlock a $3 billion market and transition …

Legend Biotech (LEGN) CEO Exit Raises Questions, Is The Stock Still Cheap?

Legend Biotech Market Sentiment

This article provides an overview of market sentiment for Legend Biotech (LEGN), including analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with a high average price target, while short interest is rising and insider activity shows net selling. …

Legend Biotech Corp (LEGN) Valuation: PE, PB & Fair Value Analysis

Legend Biotech Corp (LEGN) has a current valuation score of 9.38, ranking 33rd out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -14.06. Key valuation metrics like P/B, P/S, and P/CF ratios have not yet been disclosed …

Legend Biotech (LEGN) Stock May Be Cheap After CEO Resignation

Legend Biotech (LEGN) shares have declined significantly over the past three years, yet valuation checks suggest the stock may be cheap. The company's P/S ratio is notably lower than industry and peer averages, indicating a cautious market sentiment despite the commercial progress of its …

Does Legend Biotech’s (LEGN) CEO Exit Reshape Confidence In Its Cell Therapy Expansion Strategy?

Legend Biotech (LEGN) CEO Exit Tests Management Stability Around Its CAR-T Multiple Myeloma Strategy

Legend Biotech recently announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and Board member, effective July 24, 2026, with CARVYKTI business unit President Alan Bash appointed as Interim CEO and Dr. Huang staying on briefly as an advisor. This leadership …